Medtronic PLC (MDT) has seen a mix of financial performance, with its stock price currently lagging the market but revenue and earnings surpassing estimates in Q2 and Q3 of fiscal 2024. Amidst FDA approvals for its Inceptiv™ spinal cord stimulator and Evolut TAVR system, raising FY24 guidance based on satisfactory outcomes emphasises its potential. On the downside, MDT's weak financial prospects, with investors enduring a loss if they invested three years ago, and the sluggish return on capital hinders positive sentiments. MDT also announced dividends for the third and fourth quarters of FY 2024.
Medtronic Plc MDT News Analytics from Tue, 22 Aug 2023 07:00:00 GMT to Thu, 09 May 2024 00:35:08 GMT -
Rating -1
- Innovation 4
- Information 8
- Rumor -2
